ABSTRACT
The terminology sustained-release will be used in this text to imply any principle that delays the release of a drug from a dosage form in a bimodal or continuous manner.
The development of sustained-release products has been ongoing in the pharmaceutical industry, ever since Smith Kline & French Laboratories marketed a sustained-release product in the early 1950s. The rationale for such a dosage form is self-evident: taking one or two doses a day is preferable to a patient over taking two to four doses daily.
